StockData

Adagio Medical vs Orchestra BioMed

ADGM and OBIO side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ADGM and OBIO compare

Orchestra BioMed is the larger company, worth 299 times as much as Adagio Medical ($428M against $1.4M).

Orchestra BioMed scores higher on the StockData Score (9 against 2 for Adagio Medical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricADGMOBIO
Size and price
Market cap$1.4M$428M
Share price$1.61$7.12
Change, 1 year97.4%70.3%
Change, 5 years−99.5%−27.8%
Beta (5Y)–1.12
Employees4186
StockData Score
Total score29 (better)
Valuation score1 (better)0
Growth score03 (better)
Performance score11
Health score05 (better)
Dividend score00
Valuation
P/S–13.4×
P/B0.1×–
FCF yield−1233%−13.8% (better)
Growth
Revenue growth (TTM)–986%
Profitability
Gross margin–99.5%
Operating margin–−181%
Net margin–−185%
FCF margin–−185%
Return on equity9.6%–
Return on invested capital−314%–
Financial health
Interest coverage−5.8×–
Current ratio0.908.26 (better)
Altman Z-score−6.29−2.31 (better)
Piotroski F-score–6
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions–46.1%
Held by insiders–56.6%
Insider net buying, 12 months$244K$6.1M (better)
Short interest, % of float–10.5%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.